URB Investments Limited (ASX: URB) will be a Listed Investment Company (LIC) looking to benefit from urban renewal and regeneration by investing in assets that have exposure to population growth and density, major infrastructure investment, housing growth, re-zoning and use of land changes and tourism growth. Washington H Soul Pattinson (ASX: SOL), one of Australia’s oldest and most respected investment houses in Australia has committed to subscribe for a minimum of 10% of the Securities under this offer.
URB Investments are raising $75 million to $300 million. They are also offering 1 Option for every share subscribed. Each Option is exercisable at $1.10 at any time before 7 April 2018. URB aims to pay out between 50% and 70% of Net Operating Profits as ordinary fully franked dividends.
URB considers that urban renewal and regeneration presents an immediate and attractive investment opportunity in Australia and an investment in URB will suit investors seeking exposure to alternative asset classes. According to URBIS Pty Ltd Research, urban renewal is the significant transformation of existing urban areas to accommodate much denser, generally mixed use environments. Australian cities are now experiencing rapid transformation through the regeneration of areas such as Pyrmont in Sydney, Subiaco in Perth and Docklands in Melbourne.
URB’s investment portfolio will be managed by Contact Asset Management Pty Ltd (Contact), who have a proven track record and an average of 22 years of experience. Contact is currently the manager of BKI Investment (BKI), a LIC which has grown significantly since listing at $173 million in 2004 to approximately $1 billion as at 31 January 2017. BKI returned a 13 year Total Shareholder Return of 11.3% per annum (inclusive of Franking Credits).
As set out in Section 5 of the prospectus, URB Investments is subject to a range of risks, including the lack of operating or performance history of the company, investment risk due to fall in value of property over the short or long term, potential conflicts of interest and possible environmental risks.
Section 734(6) disclosure: The issuer of the securities is URB Investments Limited ACN 615 320 262. The securities to be issued are ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. Anyone who wants to acquire the securities will need to complete the application form that will be in or will accompany the disclosure document (which can be done via the electronic application form which will become available by clicking the bid button above).
The company reserves the right to close the offer early.
Tap 'More Info' to get access to free research, all company releases, and invest instantly for shares.
Simble Solutions Limited (ASX: SIS) is an Australian enterprise Software as a Service (SaaS) company focused on business and resource management. Its energy management solutions are principally catered towards enterprise and SME customers to reduce and manage their energy consumption. The platform is sold via channel partnerships in Australia, UK and NZ.
Update: Firm committments of at Least $15 million have been received. Offer closing Friday 19th January.
Duxton Broadacre Farms Ltd (ASX: DBF) is expected to be the only ASX listed vehicle of its type in Australia, providing its investors with direct exposure grain production. It provides investors the opportunity to access the Australian grain industry via a portfolio of diversified dry land and irrigated broadacre farms located near Forbes in NSW.
Applications for the Rong Yu Pharmaceuticals IPO have closed via OnMarket. The company has extended the offer until 16 March.
Rong Yu Pharmaceuticals Ltd (ASX RY8) was founded in 2004 and is focussed on the development, manufacture and sale of prescription and OTC pharmaceutical products based on principles of Traditional Chinese Medicine. With revenue of A$71.4 million in FY2017, the Company’s products are sold in 28 Provinces across China via a network of over 300 wholesale distributors.